CVS Restores Zepbound, Trump Drug Pricing Data Emerges
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- STAT+ Pharmalittle reports that the public will get its first look at prices of drugs launched under President Trump’s MFN deals, which require net U.S. prices roughly equal to those in other wealthy nations.
- STAT+ Pharmalittle notes that three upcoming launch drugs—AstraZeneca’s hypertension drug Baxfendy, Novo Nordisk’s insulin Awiqli, and Arvinas/Pfizer’s cancer drug Veppanu—will be the first to reveal the practical impact of the MFN pricing pact.
- STAT+ Pharmalittle reports that CVS Health will add Eli Lilly’s weight‑loss drug Zepbound back to some formularies on Oct 1, while also removing a new‑to‑market block on Lilly’s recently launched weight‑loss pill Foundayo as of June 1.
Why it matters: Patients and insurers will see transparent pricing as the MFN‑linked launches roll out, while manufacturers face tighter margins; CVS’s Zepbound reinstatement expands coverage options for weight‑loss treatment starting Oct 1.
